Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AI-081 in Advanced Solid Tumors
NCT06635785Phase 2Recruiting
- Sponsor
- OncoC4
- Start
- Mar 2025
- Primary completion
- Jun 2027
- Modality
- Prophylactic Vaccines, Bispecific Antibodies, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 2 trial of cesalatamig in solid tumor, sponsored by OncoC4. Primary endpoints: Maximum Tolerated Dose at 21 days and Dose Limiting Toxicity at 21 days. Started Mar 2025; status: recruiting.
02
Drugs
cesalatamig
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06635785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06635785.